KALA BIO, Inc. (KALA) Research

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Market snapshot

Symbol
KALA
Price
$3.61
Day change
+26.89%
Market cap
$79.2M
P/E ratio
-1.50x
52-week range
2.03-1030
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$18.25

Recent news

  • EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch

    The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.

Peer companies

  • Abpro Corporation (ABP)
  • AIM ImmunoTech Inc. (AIM)
  • Can-Fite BioPharma Ltd. (CANF)
  • Ensysce Biosciences, Inc. (ENSC)
  • Impact BioMedical Inc. (IBO)
  • Pasithea Therapeutics Corp. (KTTA)
  • Oragenics, Inc. (OGEN)
  • Soligenix, Inc. (SNGX)

Recent insider activity

  • Purdy Brendan P. — trade (0 shares) on 2026-01-30
  • Posen Hillel D. — trade (0 shares) on 2026-01-30
  • Minkowitz Avraham — trade (0 shares) on 2026-01-30
  • Colman Yonatan C. — trade (0 shares) on 2026-01-30
  • Berger Chaim D. — trade (0 shares) on 2026-01-30

Open KALA BIO, Inc. (KALA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.